170834 ⎘
Detection or diagnosis of diseases; Haematology Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
REAGENT AND METHOD FOR DIAGNOSING THROMBOTIC EVENTS
#2COMPOSITIONS AND METHODS FOR ASSAYING PLATELET REACTIVITY AND TREATMENT SELECTION
#3NOVEL ASSAY FOR THE PLATELET BINDING ACTIVITY OF THE VON WILLEBRAND FACTOR
#4IDENTIFICATION OF PROTHROMBOTIC CONDITIONS
#5METHODS FOR DETECTING CM-TMA BIOMARKERS
#6METHODS AND MATERIALS FOR IDENTIFYING AND TREATING VACCINE-INDUCED IMMUNE THROMBOTIC THROMBOCYTOPENIA
#7RISK DETERMINATION FOR A PROTHROMBOTIC THROMBOCYTOPAENIA
#8Methods and Systems for Determining ADAMTS13 Enzyme Activity
#9Biomarkers for the Detection of Thrombosis or Coagulation-Related Disorders and Their Applications
#10METHODS AND MATERIALS FOR IDENTIFYING AND TREATING MONOCLONAL AND OLIGOCLONAL GAMMOPATHIES
#11MONOCLONAL ANTIBODY AGAINST D-DIMER AND DIAGNOSIS AGENT FOR DETECTING D-DIMER, CROSSLINKED FIBRIN AND ITS DERIVATIVES CONTAINING D-DIMER BY USING THE ANTIBODY
#12COMPOSITIONS AND METHODS FOR IDENTIFYING AND MODULATING THROMBOTIC CONDITIONS IN A CANCER PATIENT
#13A METHOD TO IDENTIFY LVAD PATIENTS WITH ELEVATED LEVELS OF BLOOD ACTIVATION USING COUPON TESTS
#14PRODUCTS AND METHODS FOR THE DIAGNOSIS AND DIFFERENTIATION OF HEPARIN-INDUCED THROMBOCYTOPENIA FROM VACCINE-INDUCED IMMUNE THROMBOTIC THROMBOCYTOPENIA AND NON-HEPARIN-INDUCED THROMBOCYTOPENIA
#15Compositions and methods for assaying platelet reactivity and treatment selection
#16CLINICAL DECISION SUPPORT SYSTEM
#17D-DIMER-SPECIFIC APTAMERS AND METHODS OF USE IN DIAGNOSTICS, THERAPEUTIC AND THERANOSTIC PURPOSES
#18ADAMTS13 COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING COMPLICATIONS OF CORONAVIRUS DISEASE
#19METHODS FOR DIAGNOSING, PROGNOSING AND MONITORING TREATMENT FOR THROMBOSIS IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
#20METHODS AND KITS FOR IDENTIFYING THROMBUS ORIGIN AND OPTIMIZING POST-ISCHEMIC EVENT TREATMENT
#21METHOD FOR DETERMINING THE RISK OF A THROMBOEMBOLIC EVENT
#22BIOMARKERS FOR PULMONARY EMBOLISM IN EXHALED BREATH CONDENSATE
#23METHOD AND DEVICE FOR MEASURING THE FIBRINOGEN CONCENTRATION IN BLOOD SAMPLES
#24METHOD FOR THE DETERMINATION OF PROTEIN S LEVELS
#25Atypical hemolytic uremic syndrome (AHUS) biomarker proteins
#26NANODIAMOND PARTICLES AND RELATED DEVICES AND METHODS
#27METHODS FOR DIAGNOSING, PROGNOSING AND MONITORING TREATMENT FOR THROMBOSIS IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
#28METHOD FOR ASSAYING D-DIMERS SPECIFIC TO VENOUS THROMBOEMBOLISM AND USE THEREOF FOR DIAGNOSING PULMONARY EMBOLISM AND DEEP VENOUS THROMBOSIS
#29NANODIAMOND PARTICLES AND RELATED DEVICES AND METHODS
#30Methods and systems for determining ADAMTS13 enzyme activity
#31Methods, Systems, And Compositions For Determining Blood Clot Formation, And Uses Thereof
#32Affinity-based detection of ligand-encoded synthetic biomarkers
#33Compositions and methods for assaying platelet reactivity and treatment selection
#34Clusterin for use in the treatment of thrombotic microangiopathies
#35NOVEL ANTIBODY FOR DETERMINATION OF ADAMTS-13 ACTIVITY
#36Nanodiamond particles and related devices and methods
#37DIAGNOSIS OF CARDIOVASCULAR DISEASE
#38Binding assay for the diagnosis of a heparin-induced thrombocytopenia
#39Reagents and methods for detecting PNH type II white blood cells and their identification as risk factors for thrombotic disorders
#40Method for diagnosing disseminated intravascular coagulation (DIC)
#41Monoclonal antibody against D-dimer and diagnosis agent for detecting D-dimer, crosslinked fibrin and its derivatives containing D-dimer by using the antibody
#42Activation assay for the diagnosis of a heparin-induced thrombocytopenia
#43Method for diagnosing APS using determination of anti-PAR1 antibodies
#44NOVEL ARTIFICIAL PHOSPHOLIPID-PROTEIN BIOCONJUGATES FOR BIOMOLECULAR RECOGNITION
#45Future cardiac event biomarkers CCL3, CCL5, and CCL18
#46Methods and systems for determining ADAMTS13 enzyme activity
#47Thrombin-thrombomodulin fusion proteins as protein C activators
#48NMR methods for monitoring blood clot formation
#49Methods and kits for determining von willebrand factor activity in the absence of ristocetin
#50KITS FOR INDENTIFYING AND TREATING SUBJECTS RESISTANT TO ACETYL SALICYLIC ACID
#51Method of detecting platelet activating antibodies that cause heparin-induced thrombocytopenia/thrombosis
#52NOVEL ANTI-FIBROBLAST ACTIVATION PROTEIN (FAP) ANTIBODIES AND USES DERIVED THEREOF
#53Identification of novel disease states using viscoelastic analysis in the presence of a thrombolytic agent
#54Reagents and methods for detecting PNH type II white blood cells and their identification as risk factors for thrombotic disorders
#55ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) BIOMARKER PROTEINS
#56Methods, devices, and systems for microfluidic stress emulation
#57Detection of shed CD31, diagnosis of atherothrombosis and autoimmune disorders, and methods for analyzing signaling pathways
#58Detection of platelet-derived shed CD31
#59Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
#60Method of detection of platelet-activating antibodies that cause heparin-induced thrombocytopenia/thrombosis
#61Methods and kits for determining von Willebrand factor activity in the absence of ristocetin
#62Methods of treatment of HSCT-associated thrombotic microangiopathy with eculizumab
#63METHOD FOR PREDICTING TREATMENT RESPONSE AND TEST FOR SAFE USE OF MESENCHYMAL STEM CELLS ON INFLAMMATORY DISEASES
#64Atypical hemolytic uremic syndrome (AHUS) biomarker proteins
#65COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISEASE
#66REAGENT FOR MEASURING TOTAL PROTEIN S ACTIVITY
#67Apparatus for Analyzing the Process of Formation of Aggregates in a Biological Fluid and Corresponding Method of Analysis
#68NMR methods for monitoring blood clot formation
#69PERFUSION DEVICE, CORRESPONDING APPARATUS USING SAID PERFUSION DEVICE AND METHOD TO ANALYZE THE THROMBOTIC-ISCHEMIC AND HEMORRHAGIC PATHOLOGY
#70Antibody against insoluble fibrin
#71Application of N-terminomics to NETosis in inflammation
#72Genetic assay to determine prognosis in Polycythemia Vera patients
#73NT-proCNP as a biomarker of vascular disorders and pregnancy complication
#74ANKRD26 AS A MARKER FOR DIAGNOSIS OF THROMBOCYTOPENIAS
#75Anti-thrombotic compositions and methods for assaying platelet reactivity and treatment selection
#76Use of integrin beta subunits in the diagnosis of venous thromboembolism
#77Detection of platelet-derived shed CD31
#78METHODS AND SYSTEMS FOR MEASURING WHOLE BLOOD PLATELET REACTIVITY
#79Affinity-based detection of ligand-encoded synthetic biomarkers
#80REAGENTS AND METHODS FOR DETECTING PNH TYPE II WHITE BLOOD CELLS AND THEIR IDENTIFICATION AS RISK FACTORS FOR THROMBOTIC DISORDERS
#81Multi-parameter thrombotic assay apparatus, systems, and methods
#82NMR methods for monitoring blood clot formation
#83Method for the early detection of renal disease using proteomics
#84Method and kits for determining platelet susceptibility to activation in a patient
#85Anti-FDP monoclonal antibody, FDP measurement reagent and reagent kit using same, and FDP measurement method
#86Reagent and reagent kit for measurement of FDP, and measurement method
#87REAGENTS AND METHODS FOR DETECTING PNH TYPE II WHITE BLOOD CELLS AND THEIR IDENTIFICATION AS RISK FACTORS FOR THROMBOTIC DISORDERS
#88Diagnosing and managing venous thromboembolism and intracardiac thrombi using a provoked D-dimer test
#89Treatment of cardiovascular disease and thrombosis
#90Determination of von Willebrand Factor cleavage by ADAMTS13
#91Method For Diagnosing Thrombophilia
#92METHODS AND MATERIALS FOR ASSESSING A MAMMAL'S SUSCEPTIBILITY FOR VENOUS THROMBOEMBOLISM
#93Naphthalene-based inhibitors of anti-apoptotic proteins
#94Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2)
#95Method for in vitro assay of the circulating tissue factor, and use in the detection of coagulation diseases
#96Detection of shed CD31, diagnosis of atherothrombosis and autoimmune disorders, and methods for analyzing signaling pathways
#97D-dimer, troponin, and NT-proBNP for pulmonary embolism
#98Future cardiac event biomarkers CCL3, CCL5 and CCL18
#99One step nanosensor for single and multidrug resistance in acute coronary syndrome (ACS)
#100Complement-mediated thrombophilic assay
#101Naphthalene-based inhibitors of anti-apoptotic proteins
#102Glutamate receptor antagonists and methods of use
#103Methods for measuring platelet reactivity of individuals treated with drug eluting stents
#104Compositions and Methods for Modulation of ADAMTS13 Activity
#105Methods and kits for determining von willebrand factor activity in the absence of ristocetin
#106METHOD TO IDENTIFY AND TREAT SUBJECTS RESISTANT TO ACETYL SALICYLIC ACID
#107Diagnosis of cardiovascular disease
#108Fungal phytotoxin fusicoccin for the treatment and diagnosis of coagulation-correlated pathologies
#109METHOD FOR DETECTING DEEP VENOUS THROMBOSIS
#110Immunological assay for plasmin-digested products of stabilized fibrin
#111Materials and methods for the detection of nitrated fibrinogen
#112Dyslipoproteinemia Associated with Venous Thrombosis
#113Method of detecting platelet thrombosis or organ failure
#114Method of detecting thrombosis by measuring von Willenbrand factor-cleaving protease
#115Methods and compositions for the diagnosis of venous thromboembolic disease
#116Methods for measuring platelet reactivity of patients that have received drug eluting stents
#117Method for the Early Detection of Renal Disease Using Proteomics
#118Medicament for the protection against thrombotic diseases
#119Dyslipoproteinemia associated with venous thrombosis
#120Solid phase immobilization of phospholipids and cofactor proteins via covalent attachment
#121Methods for detecting TAFIa or TAFIai
#122Methods, systems, and compositions for determining blood clot formation, and uses thereof